Back to top
more

ETFMG Treatments, Testing and Advancements ETF: (GERM)

(Delayed Data from NYSE) As of Feb 26, 2021 04:00 PM ET

 Add to portfolio

$38.44 USD

38.44
13,384

+0.14 (0.37%)

Volume: 13,384

Zacks ETF Rank More Info

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

ETF Quote Details

Previous Close 38.30
Open 38.15
Bid 38.00
Ask 38.49
Day Low-High 37.30-38.74
52wk Low-High 23.80-44.69
Volume 13,384
NAV (month end) 39.34
Premium (+)/Discount (-) (month end)-1.04

Zacks Premium Research for GERM

Zacks ETF Rank More Info

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

 NA
ETF Risk More Info

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

NA
ETF Snapshot

ETF Expense Ratio

Expense Ratio 0.68%
Dividend (Yield) $0.28 (0.74%)
Issuer ETF MANAGERS

Benchmark for GERM

PRIME TREATMENTS TESTING & ADVNCMNTS ID

The Prime Treatments, Testing and Advancements Index provides investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.

Fund Summary for GERM

ETFMG TREATMENTS TESTING & ADVNCMNTS ETF

The ETFMG Treatments, Testing and Advancements ETF provides investment results that, before fees and expenses, correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index.